Elanco previously said it anticipates divesting "a small portfolio of products across both organizations" with total 2018 revenue of approximately $120 million to $140 million. With these two ...

Elanco has made the independent decision to divest global rights to Osurnia, which had 2018 annual revenue of $31.2 million, with intent to advance the previously announced acquisition of Bayer AG ...

Osurnia had 2018 annual revenue of $31.2 million. Dechra Pharma expects the acquisition to be earnings enhancing for the financial year ending 30 June 2021.

OSURNIA has the potential to help improve compliance in treating canine otitis externa, due to its convenient gel formulation and administration schedule that calls for two doses, one week apart.

Osurnia is a long acting treatment for otitis externa (inflammation of the outer ear) in dogs. Osurnia was launched in 2014 and is currently approved in a number of countries including major ...

Osurnia is a long acting treatment for otitis externa (inflammation of the outer ear) in dogs. Dechra is acquiring the worldwide marketing rights; the rights to the intellectual property; the ...

It was in early January that Elanco agreed to divest Osurnia, a treatment for otitis externa in dogs, to Dechra for $135 million. This deal is related to Elanco's acquisition of Bayer AG's (BAYZF ...

Elanco made announcements of the Osurnia and CapStar divestitures in January. A spokesperson said the sale of U.S. rights to StandGuard to Neogen was not unexpected.

The Commerce Commission has granted clearance to Dechra Pharmaceuticals PLC, Dechra Limited and Dechra Veterinary Products LLC to acquire the assets, rights and liabilities relating to Osurnia ...

It was in early January that Elanco agreed to divest Osurnia, a treatment for otitis externa in dogs, to Dechra for $135 million. This deal is related to Elanco's acquisition of Bayer AG's (BAYZF ...